Conjunctival Changes Induced By Prostaglandin Analogues And Timolol Maleate: A Histomorphometric Study

Purpose: To compare histological changes induced by antiglaucoma medications in the rabbit conjunctiva. Methods: Fifty New Zeland rabbits were divided in 5 groups 10 animals. The left eyes were treated daily with one drop of bimatoprost 0.03%, travoprost 0.004%, latanoprost 0.005%, timolol maleate 0.5% or artificial tears containing benzalkonium chloride (BAK) for 30 days. The right eyes served as control. Superior limbic conjunctival biopsies were performed at the 8th and 30th day in 5 rabbits of each group. The conjunctive was fixed with 10% formaldehyde, followed by He and PAS staining. Morphohistometric quantitative analyses were performed to evaluate the following parameters: inflammatory infiltrate, epithelial thickness number of goblet cells, diameter and number of blood vessels. Results: At the 8th and 30th posttreatment days, all groups, except one that received artificial tears, exhibited a diffuse inflammatory infiltrate, composed by lymphocytes and neutrophils, which was denser in the timolol group than in the prostaglandin (PG) analogues groups. At the 30th day, the timolol group showed an increased subepithelial collagen density and a significant increase in epithelial thickness (p=0.0035). The goblet cell density was significantly increased at the 8th day in the group treated with travoprost (p=0.0006), and at the 30th day in those treated with bimaprost (p=0.0021) and latanoprost (p=0.009). Conclusions: Although a moderate, diffuse inflammatory infiltrate was observed in PG-treated eyes, no changes in conjunctival epithelial thickness or subconjunctival collagen density were observed with these medications, suggesting that these drugs induce fewer changes than timolol maleate in the rabbit conjuctiva.706910916Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):714-20discussion 829-30. Comment in: Arch Ophthalmol. 2004;122(7):1088-9author reply 1089Ritch, P., Shields, B., Krupin, T., Pharmacology The glaucomas, 3 (C1996), pp. 1375-1489. , Ritch R, Shields MB, Krupin T, editors, 2nd ed. St. Louis: Mosby;Lindén, C., Therapeutic potential of prostoglandin analogues in glaucoma (2001) Expert Opin Investig Drug, 10 (4), pp. 679-694Noecker, R.S., Dirks, M.S., Choplin, N., Bimatoprost/Latanoprost Study Group. Comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: A 12-week, randomized, masked-evaluator multicenter study (2003) Am J Ophthalmol, 137 (1), pp. 210-211Parrish RK, Palmberg P, Shen WPXLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135(5):688-703Stewart, W.C., Kolker, A.E., Stewart, J.A., Leech, J., Jackson, A.L., Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost (2003) Am J Ophthalmol, 135 (3), pp. 314-320Feldman, R.M., Conjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertension (2003) J Ocul Pharmacol Ther, 19 (1), pp. 23-35Johnstone, M.A., Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost (1997) Am J Ophthalmol, 124 (4), pp. 544-547Kook, M.S., Lee, K., Increased eyelid pigmentation associated with use of latanoprost (2000) Am J Ophtalmol, 129 (6), pp. 804-806Pfeiffer, N., Griesrson, I., Goldsmith, H., Hochgesand, D., Winkgen-Böhres, A., Appleton, P., Histological effects in the iris after 3 months of latanoprost therapy: The Mainz 1 study (2001) Arch Ophtalmol, 119 (2), pp. 191-196Teus, M.A., Arranz-Marquez, E., Lucea-Suescun, P., Incidence of iris colour change in latanoprost treated eyes (2002) Br J Ophthalmol, 86 (10), pp. 1085-1088Arcieri, E.S., Santana, A., Rocha, F.N., Guapo, G.L., Costa, V.P., Blood-aqueous barrier changes after the use of prostaglandin analogues in patients with pseudophakia and aphakia: A 6-month randomized trial (2005) Arch Ophthalmol, 123 (2), pp. 186-192Brandt, J.D., Wittpenn, J.R., Katz, L.J., Steinmann, W.N., Spaeth, G.L., Conjunctival impression cytology in patients with glaucoma using long-term topical medication (1991) Am J Ophthalmol, 112 (3), pp. 297-301Mietz, H., Shlötzer-Schrehardt, U., Strassfeld, C., Krieglstein, G.K., Effect of latanoprost and timolol on the histopathology of the rabbit conjunctiva (2001) Invest Ophthalmol Vis Sci, 42 (3), pp. 679-687Miatz, H., Esser, J.M., Welsandt, G., Kociok, N., Hueber, A., Joussen, A., Latanoprost stimulates secretion of matrix metalloproteinases in tenon fibroblasts both in vitro and in vivo (2003) Invest Ophthalmol Vis Sci, 44 (12), pp. 5182-5188Costagliola, C., Prete, A.D., Incorvaia, C., Fusco, R., Parmeggiani, F., Di Giovanni, A., Ocular surface changes induced by topical application of latanoprost and timolol: A short-term study in glaucomatous patients with and without allergic conjunctivitis (2001) Graefes Arch Clin Exp Ophthalmol, 239 (11), pp. 809-814Herrems JM, Pastor JC, Calonge M, Asensio VM. Ocular surface alteration after long-term treatment with antiglaucomatious drug. Ophthalmology. 199299(7):1082-8. Comment in: Ophthalmology. 1993;100(3):293-4Broadway, D.C., Grierson, I., O'Brien, C., Hitchings, R.A., Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile (1994) Arch Ophthalmol, 112 (11), pp. 1437-1445Broadway DC, Grierson I, O'Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994;112(11):1446-54. Comment in: Arch Ophthalmol. 1995;113(7):849-50Lavin, M.J., Wormald, R.P., Migdal, C.S., Hitchings, R.A., The influence of prior therapy on the success of trabeculectomy (1990) Arch Ophthalmol, 108 (11), pp. 1543-1548Baudouin, C., Garcher, C., Haouat, N., Bron, A., Gastaud, P., Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma (1994) Ophthalmology, 101 (3), pp. 454-460Aragona, P., Candela, V., Caputi, A.P., Micali, A., Puzzolo, D., Quintieri, M., Effects of a stable analogue of PGE2 (11-deoxy-13,14-didehydro-16 (S)- methylester methyl PGE2: FCE 20700) on the secretory processes of conjunctival globet cells of rabbit (1987) Exp Eye Res, 45 (5), pp. 647-654Baudouin, C., Side effects of antiglaucomatous drugs on the ocular surface (1996) Curr Opin Ophthalmol, 7 (2), pp. 80-86Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint Jean M. Béchetoille A. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999106(3):556-63. Comment in: Ophthalmology. 1999106(10):1853Blondin, C., Hamard, P., Cholley, B., Haeffner-Cavaillon, N., Baudouin, C., In vitro effects of preserved or preservative-free antiglaucoma medications on human complement system (2003) Curr Eye Res, 27 (4), pp. 253-259Broadway, D., Hitchings, R., Grierson, I., The affect of topical anti-glaucomatous medications on the cell profile of the conjunctiva (1993) Curr Opin Ophthalmol, 4, pp. 51-57Addicks, E.M., Quigley, H.A., Green, W.R., Robin, A.L., Histologic characteristics of filtering blebs in glaucomatous eyes (1993) Arch Ophthalmol, 101 (5), pp. 795-798Gwynn, D.R., Stewart, W.C., Pitts, R.A., McMillan, T.A., Hennis, H.L., Conjunctival structure and cell counts and the results of filtering surgery (1993) Am J Ophthalmol, 116 (4), pp. 464-468Sherwood, M.B., Grierson, I., Millar, L., Hitchings, R.A., Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients (1989) Ophthalmology, 96 (3), pp. 327-335Mietz, H., Niesen, U., Krleglstein, G.K., The effect of preservatives and antiglaucomatous medication on the histopathology of the conjunctiva (1994) Graefes Arch Clin Exp Ophthalmol, 232 (9), pp. 561-565Bensoussan, I., Blondin, C., Baudouin, C., Hamard, P., Sabeh Afaki, G., Creuzot-Garcher, C.A., Flow cytometic analysis of HLA-DR, IL-6 and IL-8 expression by conjunctival epithelial cells from patients with prolonged topical antiglaucoma treatments] (2003) J Fr Ophtalmol, 26 (8), pp. 762-769Guenoun, J.M., Baudouin, C., Rat, P., Pauly, A., Warnet, J.M., Brignole-Baudouin, F., In vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cells (2005) Invest Ophthalmol Vis Sci, 46 (7), pp. 2444-2450Moreno, M., Villena, A., Cabarga, C., Sanchez-Font, E., Garcia-Campos, J., Impression cytology of the conjunctival epithelium after antiglaucomatous treatment with latanaprost (2003) Eur J Ophthalmol, 13 (6), pp. 553-559Guglielminetti, E., Barabino, S., Monaco, M., Mantero, S., Rolando, M., HLA-DR expression in conjunctival cells after latanoprost (2002) J Ocul Pharmacol Ther, 18 (1), pp. 1-9Broadway, D., Hitchings, R., Grierson, I., Topical antiglaucoma therapy: Adverse effects on the conjunctiva and implications for filtration surgery (1995) J Glaucoma, 4, pp. 136-148Oh, D.J., Martin, J.L., Williams, A.J., Peck, R.E., Pokorny, C., Russell, P., Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost (2006) Invest Ophthalmol Vis Sci, 47 (3), pp. 953-963Young, L.T., Higginbotham, E.J., Zou, X.L., Farber, M.D., Effects of topical glaucoma drugs on fistulized rabbit conjunctiva (1990) Ophthalmology, 97 (11), pp. 1423-1427De Saint Jean, M., Brignole, F., Bringuier, A.F., Bauchet, A., Feldmann, G., Baudouin, C., Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells (1999) Invest Ophthalmol Vis Sci, 40 (3), pp. 619-630Bensoussan, L., Blondin, C., Baudouin, C., Hemard, P., Sabeh Afaki, G., Creuzot-Garcher, C., (2003) Flow cytometric analysis of HLA-DR, IL-6 and IL-8 expression by conjunctival epithelial cells from patients with prolonged topical antiglaucoma treatments]J Fr Ophtalmol, 26 (8), pp. 782-789Pisella, P.J., Debbasch, C., Hamard, P., Creuzot-Garchar, C., Rat, P., Brignole, F., Baudouin, C., Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: An ex vivo and in vitro study (2004) Invest Ophthalmol Vis Sci, 45 (5), pp. 1360-1368Debbasch, C., De La Salle, S.B., Brignole, F., Rat, P., Warnet, M., Baudouin, C., Cytoprotective effects of hyaluronic acid and Carbomer 934P in ocular surface epithelial cells (2002) Invest Ophthalmol Vis Sci, 43 (11), pp. 3409-341

Testing spatial noncommutativiy via the Aharonov-Bohm effect

The possibility of detecting noncommutative space relics is analyzed using the Aharonov-Bohm effect. We show that, if space is noncommutative, the holonomy receives non-trivial kinematical corrections that will produce a diffraction pattern even when the magnetic flux is quantized. The scattering problem is also formulated, and the differential cross section is calculated. Our results can be extrapolated to high energy physics and the bound $\theta \sim [ 10 {TeV}]^{-2}$ is found. If this bound holds, then noncommutative effects could be explored in scattering experiments measuring differential cross sections for small angles. The bound state Aharonov- Bohm effect is also discussed.Comment: 16 pp, Revtex 4, 2 fig, new references added. To appear in PR

Salivary gland cancer in Southern Brazil: a prognostic study of 107 cases

Background: Salivary gland cancers (SGC) represent an uncommon group of heterogeneous tumors. We performed a retrospective survey of SGC diagnosed in a reference center for treatment of malignant tumors from the south of Brazil aiming to determine the prognostic value of demographic, clinic and pathologic features. Material and Methods: Cases diagnosed as SGC between 2006 and 2016 were retrospectively collected. Medical records were examined to extract demographic, clinic, pathologic and follow-up information. Results: One-hundred and seven cases of SGC were identified. The most common SGC were mucoepidermoid carcinoma (MEC) (n = 39) followed by adenoid cystic carcinoma (AdCC) (n = 29). Among AdCCs, 55.2% of cases were classified as cribriform, 27.6% as tubular and 17.2% as solid. The tubular subtype had the highest percentage of cases with perineural invasion (p=0.01). Among MEC, 61.5% of cases were classified as low grade, 15.4% as intermediate grade and 19.9% as high grade. Low grade MEC had the lowest percentage of cases with perineural invasion (p=0.04). The 5-year survival for loco-regional control, disease-free survival (DFS) and disease-specific survival were 75%, 70% and 84%, respectively. The following features were associated with poor DFS: advanced age (p=0.03), rural residency (p=0.01), being a smoker or former smoker (p=0.01), pain (p=0.03), nodal metastasis (p<0.001), need for chemotherapy (p=0.02), neck dissection (p=0.04), perineural invasion (p=0.01), and being diagnosed with AdCC compared to MEC (p=0.02). Conclusions: The clinco-demographic and pathologic features identified as prognostic factors reveal the profile of patients at increased risk of recurrence and who would benefit from closer follow-up

RICORS2040 : The need for collaborative research in chronic kidney disease

Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is 'solved' by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020-2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Combination of searches for heavy spin-1 resonances using 139 fb−1 of proton-proton collision data at √s = 13 TeV with the ATLAS detector

A combination of searches for new heavy spin-1 resonances decaying into diferent pairings of W, Z, or Higgs bosons, as well as directly into leptons or quarks, is presented. The data sample used corresponds to 139 fb−1 of proton-proton collisions at √s = 13 TeV collected during 2015–2018 with the ATLAS detector at the CERN Large Hadron Collider. Analyses selecting quark pairs (qq, bb, tt¯, and tb) or third-generation leptons (τν and τ τ ) are included in this kind of combination for the frst time. A simplifed model predicting a spin-1 heavy vector-boson triplet is used. Cross-section limits are set at the 95% confdence level and are compared with predictions for the benchmark model. These limits are also expressed in terms of constraints on couplings of the heavy vector-boson triplet to quarks, leptons, and the Higgs boson. The complementarity of the various analyses increases the sensitivity to new physics, and the resulting constraints are stronger than those from any individual analysis considered. The data exclude a heavy vector-boson triplet with mass below 5.8 TeV in a weakly coupled scenario, below 4.4 TeV in a strongly coupled scenario, and up to 1.5 TeV in the case of production via vector-boson fusion